Home / CANCER BUZZ Podcast


Want the latest BUZZ? Just listen in!

The CANCER BUZZ podcast features fresh perspectives on hot topics in oncology care delivery. CANCER BUZZ is where stakeholders from the front lines of care to the C-suite, from research to the registry, from chairside to benchside, talk about top-of-mind questions and real-world impact.

Listen to the CANCER BUZZ podcast on Apple PodcastsSpotify, Amazon Music, or wherever you get your podcasts. You can now listen with your smart home device. For instructions on how to listen with Alexa, click here, or just tell Alexa to "Play CANCER BUZZ." For Google Home instructions, click here.

Filter By Topic

Filter By Podcast Format

CANCER BUZZ spoke to Melissa Frey, MD, MS, and Leigha Senter, MS, CGC to discuss germline and somatic testing for patients with ovarian cancer.
CANCER BUZZ previews the sessions, people and topics of this week’s ACCC 40th National Oncology Conference. We interview Kathy Oubre, MS, CEO of the Pontchartrain Canter Center, about helping patients overcome access barriers to biomarker testing.
It is important for the cancer team to be able to recognize what a small cell might look like — such as central location of the tumor, bulky adenopathy generally.
To standardize comprehensive biomarker testing in patients with NSCLC, Oncology Hematology Care, Inc., developed and implemented a 1-year quality improvement (QI) project that included custom data reports and monitoring dashboards to ensure practice-wide adoption and sustainability across multiple clinic sites.
To celebrate its 100th episode, CANCER BUZZ talks to ACCC Board Member and Treasurer Dr. Nadine Barrett about her journey with the Association of Community Cancer Centers.
While not yet mainstream in the community setting, hear how measurable residual disease (MRD) testing has the potential to become more fully integrated into clinical practice as one of the reliable markers of treatment response for patients with multiple myeloma and chronic lymphocytic leukemia.
Biomarker testing is crucial to precision medicine, but barriers still exist. Learn from two healthcare advocates about recent policy changes designed to ensure better access to biomarker testing.
Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC.
Genetic counselors—as members of the cancer care team—can help patients better understand their cancer diagnosis, make informed treatment decisions, and navigate the financial costs of testing.
Learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.
Learn how genetic healthcare services have adapted to virtual care delivery, and what challenges face its widespread use after the COVID-19 pandemic is over.
Learn about the latest promising breakthroughs in immunotherapy, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.
Learn about the role of financial navigation in helping patients and providers understand the options available to patients in need of biomarker testing.
Learn about dermatology’s role in the cancer care continuum and how cancer teams can better integrate dermatology into the immunotherapy care process.
We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.
Learn about the mental health implications of treatment with cancer immunotherapy, and how cancer care providers can better integrate mental health awareness into the IO care continuum.
We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.
Learn why a trip to the emergency department is different for patients who receive immunotherapy for cancer, what information helps ED clinicians, and what busy emergency department providers need to know about immune-related adverse events.
Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.